Welcome to the
Biogen Newsroom

Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories.

Latest News

August 3, 2022
EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401)

July 28, 2022
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpoint Biogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ

July 26, 2022
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S., 1 it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be the first treatment to target a genetic cause of ALS 12-month data included in the filing show

Lab Picture

Latest News

See Our Latest Tweets

Biogen Statements
Biogen Statements

See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives.

Annual Report
Annual Report

Review our annual reports to see performance highlights, financials, SEC filings, stock information and more.

Sustainability Report
ESG Report: 2021 Year in Review

Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.

Connecting the dots in neuroscience

Can research targeting one neurological disorder drive advancements for other diseases? Chris Henderson, Head of Research at Biogen, explains how experience in one disease can accelerate development of treatments for others.

Chris Henderson
Alzheimer

Innovation in Alzheimer's

We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen.

health
Healthy Climate, Healthy Lives™

Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity.

Read More
Diversity
Diversity, Equity and Inclusion

We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve.

Read More
Corporate Responsibility

Our Commitment to Corporate Responsibility

Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive.

Request Multimedia Resources

For Media Professionals

Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need.

Get Biogen Updates Delivered to Your Inbox

Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.”

Sign Up for Biogen Alerts
Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts.